China-based CSPC Pharmaceutical Group Limited (HKEX: 01093) announced receipt of US FDA Fast Track Designation for SYS6090 (JMT108), which CSPC describes as a potential first-in-class PD-1/IL-15 bispecific fusion protein, for the treatment of patients with microsatellite-stable (MSS) or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) who have progressed on standard systemic therapies.
MSS/pMMR mCRC has historically shown limited responsiveness to checkpoint inhibitors. Median overall survival in patients receiving third-line or later therapy remains under 12 months, according to CSPC. The company said the designation was supported by preclinical data and Phase I clinical study results from ongoing trials in both China and the United States, including the first-in-human NCT06877650. No specific response rates, patient numbers, or p-values have been publicly disclosed.
SYS6090 is designed with an asymmetric bispecific structure that simultaneously blocks PD-1 and activates IL-15 signaling in a PD-1-dependent manner, intended to direct cytokine activity selectively toward PD-1-expressing tumor-infiltrating immune cells rather than systemically. The company said this design aims to reactivate exhausted effector cells in immunologically cold tumors while limiting systemic immune-related toxicity.
The company received Fast Track Designation, meaning more frequent FDA interactions and potential eligibility for rolling review and Priority Review if relevant criteria are subsequently met. One week prior to this announcement, the company initiated a Phase Ib/II trial of SYS6090 in hepatocellular carcinoma at the first center in China, following National Medical Products Administration (NMPA) approval in July 2026.
Spot something wrong? Report an issue with this article